|
Sex
| | |
0.006
|
|
Men
|
37 (92.5)
|
67.6
| |
|
Women
|
3 (7.5)
|
0.0
| |
|
Agea (years)
|
58 (41–80)
| | |
|
ECOG performance status
| | |
0.267
|
|
0–1
|
11 (27.5)
|
68.2
| |
|
2
|
29 (72.5)
|
55.2
| |
|
Primary tumor location
| | |
0.403
|
|
Upper
|
12 (30.0)
|
50.0
| |
|
Middle
|
26 (65.0)
|
65.4
| |
|
Lower
|
2 (5.0)
|
100.0
| |
|
T category of primary tumorb
| | |
0.392
|
|
T1
|
2 (5.0)
|
100.0
| |
|
T2
|
3 (7.5)
|
100.0
| |
|
T3
|
21 (52.5)
|
57.1
| |
|
T4
|
14 (35.0)
|
57.1
| |
|
Clinical stage of primary tumorb
| | |
0.526
|
|
IIA–IIB
|
2 (5.0)
|
100
| |
|
IIIA–IIIC
|
29 (72.5)
|
62.1
| |
|
IV
|
9 (22.5)
|
55.5
| |
|
NRS score of 3–4c
|
|
Before nutrition support
|
22 (55.0)
|
–e
| |
|
After nutrition support
|
6 (15.0)
|
–
| |
|
Hemoglobin level after CCRTa (g/L)
|
110 (56–156)
|
–
| |
|
Total energy intakea (kcal/day)
|
2166 (1956–2213)
|
–
| |
|
Total protein intakea (g/kg per day)
|
1.53 (1.41–1.76)
|
–
| |
|
Fistula closure
|
32 (80.0)
|
–
| |
|
Time to fistula closurea (weeks)
|
5 (2–11)
|
–
| |
|
Fistula site
| | |
0.435
|
|
Trachea and bronchus
|
7 (17.5)
|
57.1
| |
|
Mediastinum
|
33 (82.5)
|
63.6
| |
|
Radiation dosea (Gy)
|
60 (46–68)
| |
<0.001
|
|
<60
|
14 (35.0)
|
50.0
| |
|
≥60
|
26 (65.0)
|
69.2
| |
|
Concurrent chemotherapy
| | |
0.333
|
|
DDP + 5-FU
|
7 (17.5)
|
42.9
| |
|
Docetaxel-based regimens
|
33 (82.5)
|
66.7
| |
|
Clinical tumor response after CCRT
| | |
<0.001
|
|
CR
|
12 (30.0)
|
91.7
| |
|
PR
|
20 (50.0)
|
65.0
| |
|
SD
|
3 (7.5)
|
33.3
| |
|
PD
|
5 (12.5)
|
0
| |
